Search EN menu
 
 Homepage

As an LGBTIQ inclusive employer, we celebrate the Luxembourg Pride Week.

See more  
en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

ORION PHARMACEUTICALS RDI

Signature(s)

Amount
€ 100,000,000
Countries
Sector(s)
Finland : € 100,000,000
Industry : € 100,000,000
Signature date(s)
15/12/2006 : € 50,000,000
15/12/2006 : € 50,000,000
Link to source
Data sheet
ORION PHARMACEUTICALS RDI
Other links
Summary sheet
Orion Pharmaceuticals RDI (Finland)

Summary sheet

Release date
13 January 2005
Status
Reference
Signed | 15/12/2006
20040414
Project name
Promoter - financial intermediary
Orion Pharmaceuticals RDI (Finland)
Orion Corporation
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
Loan of up to EUR 150 million
EUR 300 million
Location
Sector(s)
Description
Objectives

The project comprises numerous initiatives for discovery and production of pharmaceuticals in selected core therapeutic areas (central nervous system, cardiovascular diseases and hormonal therapies).

The Project would support the company’s RDI expenditure aimed at producing proprietary original pharmaceutical innovations. It corresponds to EU policy and the objectives of the Bank’s Innovation 2010 Initiative to bolster investments in human capital, and industrial innovation and research.

Environmental aspects
Procurement

The expected increase in R&D activities will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11/EC.

The promoter, as a private company is not bound by EU Directives on procurement. R&D activities are generally carried out by the promoter research staff. Procedures for procuring specialized equipment and external services will be varified during appraisal.

Comments

i2i – Research, development and innovative investments (RDI), as well as creation and diffusion of new technologies.

Link to source
Summary sheet
Orion Pharmaceuticals RDI (Finland)
Other links
Data sheet
ORION PHARMACEUTICALS RDI

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications